about
Low bone density in patients receiving methadone maintenance treatment.A web-based Alcohol Clinical Training (ACT) curriculum: is in-person faculty development necessary to affect teaching?Update in pain medicine.Opioids for chronic pain in patients with substance abuse: too much, too little or just right?Internal medicine residency training for unhealthy alcohol and other drug use: recommendations for curriculum design.Physician introduction to opioids for pain among patients with opioid dependence and depressive symptomsLow vitamin d status of patients in methadone maintenance treatmentCollaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experienceA transitional opioid program to engage hospitalized drug users.Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain.Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.Chronic back pain with possible prescription opioid misuse.Screening for unhealthy alcohol and other drug use by health educators: do primary care clinicians document screening results?Treating homeless opioid dependent patients with buprenorphine in an office-based setting.Are opioid dependence and methadone maintenance treatment (MMT) documented in the medical record? A patient safety issue.Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.Commentary on letter entitled, "buprenorphine comes of age".Clinical case discussion: treating opioid dependence with buprenorphine.Safe opioid prescribing: a long way to go.JAMA patient page. Misuse of opioid medication.Addressing smoking cessation in methadone programs.Update in addiction medicine for the generalist.Update in pain medicine
P50
Q33251399-4429294C-9452-4936-8F4A-287847E74714Q33322931-7F4D8BFD-31DD-45AE-AE6A-977AB0481657Q33323179-D314185F-DBD7-4DF8-BB38-C44F8421B6F3Q33486862-76940D09-C7A2-46EB-B9B6-236EFD2E5D55Q33540851-447EE62A-4DB4-457A-9D69-FB4675DA6548Q33667899-C92FA07F-9EE9-40AC-947B-A85B759040AEQ33763986-96B2567F-9F44-4E61-9DDD-809AFF0C9E9AQ33845768-8B11C8F7-9CF1-4FB8-895B-E91924CA3EFAQ33959695-FA8AFD81-8C66-4260-ADDE-9DF58837F653Q34118245-4E6E5FDE-03A5-4502-A69B-ED9904050DD6Q34485532-31FE3CE3-934D-4C0B-AF6D-F972D77E4BC3Q34609419-7F67EC03-CE73-49C5-9FCC-E8D90485B8CEQ34681176-EA2DEA0C-79E4-4827-AF1A-EBF715DC1E65Q35683055-17664165-0730-4CFE-AAE2-4501BA437DFBQ37305173-451BA5A8-53F5-4634-B55D-392C6512F4A3Q37951361-953F458C-AAA8-4CF4-8E58-88A5EE08FF15Q42730422-B90B7D7F-DED5-4356-A57E-F000CD1BAE99Q42730453-1F0D6F2C-D6F4-4BFE-A7FB-5324FD6F5CD9Q42870106-C57A720F-73D0-41E2-9D82-EEA3AC10473CQ44339408-CCA78E22-F0E6-4403-9FFD-3F2170159EADQ46398232-A1E433F8-C598-4B7E-880B-E8002A2D703EQ51903799-7085EDCF-BBA8-44AB-8485-1AC9C888738CQ60149937-0F5BFEF6-AE3C-4D46-8C5E-3432D531CB24
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniel P Alford
@ast
Daniel P Alford
@en
Daniel P Alford
@es
Daniel P Alford
@fr
Daniel P Alford
@nl
Daniel P Alford
@sl
type
label
Daniel P Alford
@ast
Daniel P Alford
@en
Daniel P Alford
@es
Daniel P Alford
@fr
Daniel P Alford
@nl
Daniel P Alford
@sl
prefLabel
Daniel P Alford
@ast
Daniel P Alford
@en
Daniel P Alford
@es
Daniel P Alford
@fr
Daniel P Alford
@nl
Daniel P Alford
@sl
P106
P21
P31
P496
0000-0002-6250-8390